Conference abstract · 28 Sep 2015
Review articlePublished 30 May 2024
Understanding Tumor Markers: A Comprehensive Guide
Department of Psychosocial Research and Epidemiology, University of NRK, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tumor markers are biomolecules that are produced by cancer cells or by the body in response to cancer. These molecules serve as indicators of the presence of cancer, its progression, and the response to treatment. Tumor markers can be proteins, genes, hormones, enzymes, or other substances, and they are often detected in blood, urine, or tissue samples. While tumor markers are valuable tools in cancer diagnosis and management, their clinical utility varies depending on factors such as sensitivity, specificity, and the type of cancer being evaluated. This paper provides an overview of tumor markers, including their types, roles in cancer detection and monitoring, and limitations. It discusses common tumor markers used in clinical practice, such as prostate-specific antigen (PSA) for prostate cancer and CA-125 for ovarian cancer, as well as emerging markers and technologies for improved detection and characterization of tumors. Additionally, the abstract highlights the importance of integrating tumor marker testing with other diagnostic modalities and clinical assessments to optimize patient care and outcomes. Tumor markers, biological substances produced by cancer cells or by the body in response to cancer, have emerged as pivotal tools in oncology for diagnosis, prognosis, treatment monitoring, and research. These markers, ranging from proteins and enzymes to genetic materials, hold immense promise in aiding clinical decision-making and advancing our understanding of cancer biology. This abstract explores the landscape of tumor markers, delving into their diverse types, mechanisms of action, clinical applications, and challenges. We scrutinize the significance of various tumor markers in different cancer types, highlighting their utility in early detection, disease monitoring, and predicting treatment response. Furthermore, we discuss the evolving role of novel technologies such as liquid biopsies and genomic profiling in enhancing the sensitivity and specificity of tumor markers. Despite their potential, the clinical utility of tumor markers is not devoid of limitations, including issues related to specificity, standardization, and cost-effectiveness. In conclusion, this abstract underscores the pivotal role of tumor markers in modern oncology, while also emphasizing the need for continued research and innovation to maximize their clinical impact.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 14 Nov 2016
High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast CancerPatients after Surgery
Conference abstract · 20 Oct 2014
Tumor-associated antigens and their cognate autoantibodies as molecular markers for breast cancer diagnostics
Conference abstract · 13 Jul 2015
Tumor-associated carbohydrate antigen, Tn, as a cancer prognosis marker and therapeutic target
Research article · 26 Mar 2021
Evaluation of selected proinflammatory factors, angiogenesis and lymphangiogenesis as potential markers of early tumor recurrence in patients undergoing surgical treatment for prostate cancer
More from this journal
The newest in Journal of Cancer Diagnosis.
Editorial · 1 Dec 2025
Prostate Cancer Screening: Beyond PSA, Toward Precision
Editorial · 1 Dec 2025
Gynecological Screening: Evolving Guidelines, Technology, Challenges
Editorial · 1 Dec 2025
Advancing Early Cancer Detection: Precision & Equity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Diagnosis
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Riky Ruiter”
